Genetic Variants and Clinical Phenotypes in Korean Patients With Hereditary Hemorrhagic Telangiectasia

Abstract

Objectives. Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant vascular disorder characterized by recurrent epistaxis, telangiectasias, and visceral arteriovenous malformations (AVMs). Activin A receptor-like type 1 (ACVRL1/ALK1) and Endoglin (ENG) are the principal genes whose mutations cause HHT. A multicenter study to investigate the correlation between genetic variations and clinical outcomes in Korean HHT patients has been lacking.Methods. Seventy-two members from 40 families suspected of HHT based on symptoms were genetically screened for pathogenic variants in ACVRL1 and ENG. Patients with genetically diagnosed HHT were also evaluated.Results. In the HHT genetic screening, 42 patients from 24 of the 40 families had genetic variants that met the pathogenic criteria (pathogenic very strong, pathogenic strong, pathogenic moderate, or pathogenic supporting) based on ACMG Standards and Guidelines in either ENG or ACVRL1; 26 from 12 families (50%) in ENG, and 16 from 12 families (50%) in ACVRL1. The diagnostic screening of 42 genetically positive HHT patients based on the Curaçao criteria revealed that 24 patients (57%) were in the definite group, 17 patients (41%) were in the probable group, and 1 patient (2%) was in the unlikely group. Epistaxis was the most common clinical presentation (38/42, 90%), followed by visceral AVMs (24/42, 57%), and telangiectasia (21/42, 50%). Five patients (12%) did not have a family history of HHT clinical symptoms.Conclusion. Among patients having ACVRL1 or ENG genetic variants, only about half of them could be clinically diagnosed as definite HHT, suggesting that genetic screening is important to confirm the diagnosis.

Pharmacogenomic Considerations for Anticoagulant Prescription in Patients with Hereditary Haemorrhagic Telangiectasia

“…The 2020 Second International Guidelines [7] recommended obtaining a genetic diagnosis of the HHT-causative mutation to facilitate targeted screening for internal AVMs. HHT gene testing pathways are now in place in multiple countries worldwide [7,8,[18][19][20][21][22][23][24][25] and facilitate the diagnosis of HHT, targeted AVM screening programmes, and direction of SMAD4 families to SMAD4-specific preventative measures [26][27][28][29][30][31].…”

Pathogenic Variant Frequencies in Hereditary Haemorrhagic Telangiectasia Support Clinical Evidence of Protection from Myocardial Infarction

“…GDF2 heterozygous variants were initially described as causing an HHT-like syndrome [ 36 ] and, more recently, in a family meeting full Curaçao Criteria clinical designation [ 37 ]. Genetic testing for ACVRL1 , ENG , SMAD4, and GDF2 is widely performed as part of HHT diagnostics [ 21 , 22 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 ]. Genotyped patients and families are commonly referred to as HHT type 1 ( ENG , OMIM #187300), HHT type 2 ( ACVRL1 , OMIM #600376), JPHT ( SMAD4 , (OMIM ##175050), and HHT type 5 ( GDF2 , OMIM # 615506).…”